Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial

Wallack, Marc K.; Muthukumaran, S.; Balch, Charles M.; Urist, Marshall M.; Bland, Kirby I.; Murray, Douglas R.; Robinson, William A.; Flaherty, Lawrence E.; Richards, Jon M.; Bartolucci, Alfred A.; Rosen, Les

doi:10.1016/s1072-7515(98)00097-0

Cited by 167 publications

(86 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…289 A phase I study of intravesical vaccinia virus infection 289 demonstrated that vaccinia virus can be safely administrated into the bladder and gave evidence that the treatment was associated with an intense immune response with few clinical side effects. 294 Of the four patients studied, three of them survived and were free of disease at 4 years. The authors felt that the data supported further study of vaccinia virus vectors in the treatment of bladder cancer.…”

Section: Ongoing Trialmentioning

confidence: 98%

Oncolytic viral therapies

2004

View full text Add to dashboard Cite

Molecular research has vastly advanced our understanding of the mechanism of cancer growth and spread. Targeted approaches utilizing molecular science have yielded provocative results in the treatment of cancer. Oncolytic viruses genetically programmed to replicate within cancer cells and directly induce toxic effect via cell lysis or apoptosis are currently being explored in the clinic. Safety has been confirmed and despite variable efficacy results several dramatic responses have been observed with some oncolytic viruses. This review summarizes results of clinical trials with oncolytic viruses in cancer.

show abstract

Section: Ongoing Trialmentioning

confidence: 98%

Oncolytic viral therapies

2004

View full text Add to dashboard Cite

show abstract

“…A phase 1 study of intravesical vaccinia virus infection 156 demonstrated that vaccinia virus can be safely administrated into the bladder and found that the treatment was associated with an intense immune response with few clinical side effects. 157 Of the four patients studied, three survived and were free of disease at 4-year follow-up.…”

Section: Vacciniamentioning

confidence: 95%

“…Vaccinia oncolysate has been studied as a vaccine in early stage melanoma. [156][157][158][159][160][161][162][163][164][165] Results suggested a good tolerability and survival advantage compared with historical controls. However, an unpublished prospective controlled trial failed to validate the use of vaccinia oncolysate.…”

Section: Vacciniamentioning

confidence: 99%

Clinical development directions in oncolytic viral therapy

Eager

Nemunaitis

2011

Cancer Gene Ther

View full text Add to dashboard Cite

Oncolytic virotherapy is an emerging experimental treatment platform for cancer therapy. Oncolytic viruses are replicativecompetent viruses that are engineered to replicate selectively in cancer cells with specified oncogenic phenotypes. Multiple DNA and RNA viruses have been clinically tested in a variety of tumors. This review will provide a brief description of these novel anticancer biologics and will summarize the results of clinical investigation. To date oncolytic virotherapy has shown to be safe, and has generated clinical responses in tumors that are resistant to chemotherapy or radiotherapy. The major challenge for researchers is to maximize the efficacy of these viral therapeutics, and to establish stable systemic delivery mechanisms.

show abstract

“…240 In a phase I study of intravesical vaccinia virus infection, 240 it was demonstrated that vaccinia virus can be safely administrated into the bladder and gave evidence that the treatment was associated with an intense immune response with few clinical side effects. 241 The intense immune response was characterized by the following: (a ) mucosal edema and vascular ectasia; ( b) recruitment of dendritic cells to the injection site; and (c ) mucosal and submucosal infiltration by lymphocytes, eosinophils, and plasma cells into tumor and normal tissue. 241 Of the four patients studied, three of them survived and were free of disease at 4 years.…”

Section: Vacciniamentioning

confidence: 99%

“…241 The intense immune response was characterized by the following: (a ) mucosal edema and vascular ectasia; ( b) recruitment of dendritic cells to the injection site; and (c ) mucosal and submucosal infiltration by lymphocytes, eosinophils, and plasma cells into tumor and normal tissue. 241 Of the four patients studied, three of them survived and were free of disease at 4 years. The authors felt that the data supported further study of vaccinia virus vectors in the treatment of bladder cancer.…”

Section: Vacciniamentioning

confidence: 99%